ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST [Yahoo! Finance]
Unity Biotechnology, Inc. (UBX)
Last unity biotechnology, inc. earnings: 3/11 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key drug candidates have been selected for presentations, including an Oral Report, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The three drugs are olverembatinib (HQP1351), the first and only China -approved third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a Bcl-2-selective inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. This year's ASCO Annual Meeting will take place both online and in-person at the McCormick Place, Chicago, IL the United States , on May 31–June 4, 2024 (local time). "Entering the seventh consecutive year for our studies to be
Show less
Read more
Impact Snapshot
Event Time:
UBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UBX alerts
High impacting Unity Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
UBX
News
- UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual MeetingGlobeNewswire
- UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DMEGlobeNewswire
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesGlobeNewswire
UBX
Earnings
- 11/13/23 - Miss
UBX
Sec Filings
- 5/3/24 - Form 4
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- UBX's page on the SEC website